 of
disease severity, major adverse cardiovascular events and all-cause
mortality in patients with peripheral arterial disease. Vasc Med
2010;15:267-74.
26. Wilson AM, Kimura E, Harada RK, Nair N, Narasimhan B, Meng XY,
et al. Beta2-microglobulin as a biomarker in peripheral arterial disease:
proteomic proﬁling and clinical studies. Circulation 2007;116:1396-403.
27. Hiatt WR, Zakharyan A, Fung ET, Crutcher G, Smith A, Stanford C,
et al. A validated biomarker panel to identify peripheral artery disease.
Vasc Med 2012;17:386-93.
28. Joosten MM, Pai JK, Bertoia ML, Gansevoort RT, Bakker SJ,
Cooke JP, et al. b2-microglobulin, cystatin C, and creatinine and risk
of symptomatic peripheral artery disease. J Am Heart Assoc 2014;3:
e000803.
29. Cheng CH, Chen YS, Shu KH, Chang HR, Chou MC. Higher serum
levels of soluble intracellular cell adhesion molecule-1 and soluble
vascular cell adhesion molecule predict peripheral artery disease in
haemodialysis patients. Nephrology (Carlton) 2012;17:718-24.
30. Gardner AW, Parker DE, Montgomery PS, Sosnowska D,
Casanegra AI, Esponda OL, et al. Impaired vascular endothelial
growth factor a and inﬂammation in patients with peripheral artery
disease. Angiology 2014;65:683-90.
31. Pradhan AD, Rifai N, Ridker PM. Soluble intercellular adhesion
molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation
2002;106:820-5.
32. McDermott MM, Liu K, Ferrucci L, Tian L, Guralnik JM, Tao H